Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2025,
Minapharm Pharmaceuticals paidE£0 Mil more to buy back shares than it received from issuing new shares.
It spentE£2,295 Mil paying down its debt.
It paidE£0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentE£16 Mil paying cash dividends to shareholders.
It receivedE£1,752 Mil on other financial activities.
In all, Minapharm PharmaceuticalsspentE£559 Mil on financial activities for the
three
months ended in Dec. 2025.
Minapharm Pharmaceuticals (CAI:MIPH) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Minapharm Pharmaceuticals's issuance of stock for the
three
months ended in Dec. 2025 was E£0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Minapharm Pharmaceuticals's repurchase of stock for the
three
months ended in Dec. 2025 was E£0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Minapharm Pharmaceuticals's net issuance of debt for the
three
months ended in Dec. 2025 was E£-2,295 Mil.
Minapharm Pharmaceuticals spentE£2,295 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Minapharm Pharmaceuticals's net issuance of preferred for the
three
months ended in Dec. 2025 was E£0 Mil.
Minapharm Pharmaceuticals paidE£0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Minapharm Pharmaceuticals's cash flow for dividends for the
three
months ended in Dec. 2025 was E£-16 Mil.
Minapharm Pharmaceuticals spentE£16 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Minapharm Pharmaceuticals's other financing for the
three
months ended in Dec. 2025 was E£1,752 Mil.
Minapharm Pharmaceuticals receivedE£1,752 Mil on other financial activities.
Minapharm Pharmaceuticals Cash Flow from Financing Related Terms
Minapharm Pharmaceuticals Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Minapharm Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals Cash Flow from Financing Chart
Minapharm Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Minapharm Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£699 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of E£699 Mil mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Cash Flow from Financing of E£699 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Cash Flow from Financing too high?
Minapharm Pharmaceuticals' current Cash Flow from Financing is E£699 Mil. Overall, Minapharm Pharmaceuticals has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Cash Flow from Financing compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Cash Flow from Financing of E£699 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Cash Flow from Financing is E£699 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£366.08, compared to a current price of E£818.51 — trading 123.6% above its estimated fair value. The current Cash Flow from Financing is E£699 Mil. Minapharm Pharmaceuticals' overall GF Score™ is 44/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Cash Flow from Financing is E£699 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£818.51 is trading 123.6% above its estimated GF Value™ of E£366.08.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Cash Flow from Financing: E£699 Mil
GF Value™: E£366.08 vs. price of E£818.51 (123.6% above fair value)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
44GF Score
Get the complete analysis for CAI:MIPH
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
